newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Praxis Precision Medicines granted restricted stock unit awards covering 3,594 shares to six new non-executive employees.
  • The grants were made on December 1, 2025, under the 2024 Inducement Plan as inducements for new hires.
  • The awards comply with Nasdaq Listing Rule 5635(c)(4) for individuals who were not previously employed by the company.
  • The restricted stock units will vest in four equal annual installments contingent on continued employment.
  • Praxis is a clinical-stage biopharmaceutical company developing therapies for CNS disorders using its Cerebrum™ small molecule platform.
  • The company maintains a portfolio with four clinical-stage product candidates targeting epilepsy & movement disorders.